Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Malignant Ascites 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 291Drug Therapy 277Bevacizumab 249apatinib 247camrelizumab 219Etoposide 201Irinotecan 183Doxorubicin 181Leucovorin 164Dexamethasone 161pembrolizumab 155Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × molgramostim × Clear all
NCT05501340 2022-08-15

PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Second Affiliated Hospital of Soochow University

Phase 1/2 Unknown
40 enrolled

Malignant Ascites

NCT01729663 2015-09-02

Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients

Laboratorio Pablo Cassará S.R.L.

Phase 2/3 Unknown
108 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡